In-vivo assessment of CXCR4 PET-derived volumetric parameters is predictive for outcome of patients with GEP-NEC and could be used as a risk stratification tool, which detects patients prone to early progression. This evidence concerns the gene CXCR4 and neuroendocrine carcinoma.